CME

Jointly provided by the Postgraduate Institute for Medicine and DKBmed, LLC.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe factors contributing to the increasing incidence of BCC and CSCC
  • Develop strategies to improve screening for NMSC in immunosuppressed and other patients at elevated risk
  • Evaluate safety and efficacy data for medications available or in late-stage development for patients with aggressive BCC or CSCC.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Media: Enduring

Acknowledgement

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty / Presenter Reported Financial Relationship

Omid Hamid, MD

  • Consulting Fees – Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi Regeneron, Seagen, Tempus, Zelluna
  • Fees for Non-CE Services (e.g., Speakers’Bureaus) – BMS, Novartis, Pfizer, Sanofi Regeneron
  • Contracted Research – Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Sanofi Regeneron, Seagen, Torque, Zelluna

Planners and Managers

The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Contact Information

To contact Postgraduate Institute for Medicine (PIM) please visit www.pimed.com. For technical issues, please contact [email protected]

Launch Date: 12/15/2021
Expiration Date: 6/14/23